Ariele Viacava Follis

Ariele Viacava Follis has held a variety of roles in the biotechnology industry. In 2023, they began their current role as Director of Structural Biology at ROME Therapeutics. From 2021 to 2023, they were the Associate Director at Faze Medicines. From 2017 to 2021, they held three positions at EMD Serono, Inc., including Principal Scientist, Senior Scientist, and Scientist. From 2009 to 2017, they were a Postdoc at St. Jude Children's Research Hospital, where they studied protein-protein interactions that regulate transcription-independent pro-apoptotic function of the tumor suppressor p53. Ariele primarily used NMR spectroscopy to generate mechanistic hypotheses, combined with an array of biophysical, biochemical and cell culture techniques. Ariele also became interested in the chemical modulation of the pro-apoptotic effector protein BAX with small molecules.

Ariele Viacava Follis obtained a Doctor of Philosophy (Ph.D.) in Chemistry from Georgetown University between 2005 and 2009. Prior to that, they obtained a Diploma in Complexity in Science from Scuola Universitaria Superiore, Pavia between 1999 and 2004, and a Bachelor's Degree in Organic Chemistry from Università di Pavia between 1999 and 2004. Ariele also attended Liceo Classico Vittorio Alfieri between 1994 and 1999, where they obtained their High School degree.